Long-term Outcomes of Bevacizumab and Chemoradiation for Locoregionally Advanced Nasopharyngeal Carcinoma: A Nonrandomized Controlled Trial

IMPORTANCE: The long-term outcomes associated with adding bevacizumab, a vascular endothelial growth factor inhibitor, to standard chemoradiation have continued to be favorable for a group of patients with locoregionally advanced nasopharyngeal carcinoma (NPC). OBJECTIVE: To assess long-term toxic e...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Nancy Y., Harris, Jonathan, Kim, John, Garden, Adam, Mechalakos, James, Pfister, David G., Chan, Anthony T.C., Hu, Kenneth, Colevas, A Dimitrios, Frank, Steven, Shenouda, George, Bar-Ad, Voichita, Waldron, John N., Harari, Paul M., Raben, Adam, Torres-Saavedra, Pedro, Le, Quynh-Thu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2023
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10238946/
https://www.ncbi.nlm.nih.gov/pubmed/37266942
http://dx.doi.org/10.1001/jamanetworkopen.2023.16094

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10238946/
https://www.ncbi.nlm.nih.gov/pubmed/37266942
http://dx.doi.org/10.1001/jamanetworkopen.2023.16094

Ejemplares similares